# Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy

> **NCT01844297** · NA · UNKNOWN · sponsor: **Peking Union Medical College** · enrollment: 500 (estimated)

## Conditions studied

- AIDS/HIV PROBLEM

## Interventions

- **DRUG:** TDF+3TC+EFV

## Key facts

- **NCT ID:** NCT01844297
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2015-10
- **Final completion:** 2015-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2013-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844297, "Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01844297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*